Benefits

• Specialised payloads capable of performing biochemical, microbiology & chemical experiments in space
• Electronic systems integrated with payloads allowing autonomous experiments with data transmitted live back to Earth
• Unique IP and products leveraging the microgravity environment.

Technology

Part of the company’s core technology is an advanced microfluidic chip integrated with a state-of-the-art electronic sensor suite and data acquisition system. The platform can perform experiments in a confined space and controlled environment, remotely and autonomously. These experiments allow the platform to understand and control the behavioural changes of microbes in spaces, as well as aiding in the development of new pharmaceutical products.

Potential markets

The platform is configurable to facilitate research across multiple industries, ranging from life sciences and microbiology to pharmaceutical drug development.

IP status

The IP for the research results belong to customers and IP for the experimental setup belong to ResearchSat.

Partnering opportunities

ResearchSat is looking to collaborate with research organisations, academic researchers and for cubesat platforms who can host their payload. There is also a potential for partnerships with other cubesat companies to share launch costs. The company is aiming to launch their first payload into orbit by late 2020 and actively seeking research and funding partners.